- Home
- FISI vs CRVS Comparison
FISI vs CRVS Comparison
Compare FISI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- CRVS
- Stock Information
- Founded
- FISI 1817
- CRVS 2014
- Country
- FISI United States
- CRVS United States
- Employees
- FISI N/A
- CRVS N/A
- Industry
- FISI Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FISI Finance
- CRVS Health Care
- Exchange
- FISI Nasdaq
- CRVS Nasdaq
- Market Cap
- FISI 416.4M
- CRVS 451.0M
- IPO Year
- FISI 1999
- CRVS 2016
- Fundamental
- Price
- FISI $27.46
- CRVS $8.94
- Analyst Decision
- FISI Hold
- CRVS Buy
- Analyst Count
- FISI 2
- CRVS 4
- Target Price
- FISI $22.00
- CRVS $12.83
- AVG Volume (30 Days)
- FISI 41.2K
- CRVS 1.0M
- Earning Date
- FISI 10-24-2024
- CRVS 11-12-2024
- Dividend Yield
- FISI 4.44%
- CRVS N/A
- EPS Growth
- FISI N/A
- CRVS N/A
- EPS
- FISI 3.17
- CRVS N/A
- Revenue
- FISI $216,605,000.00
- CRVS N/A
- Revenue This Year
- FISI N/A
- CRVS N/A
- Revenue Next Year
- FISI $6.94
- CRVS N/A
- P/E Ratio
- FISI $8.66
- CRVS N/A
- Revenue Growth
- FISI 9.25
- CRVS N/A
- 52 Week Low
- FISI $16.29
- CRVS $1.30
- 52 Week High
- FISI $28.12
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FISI 60.29
- CRVS 60.34
- Support Level
- FISI $26.00
- CRVS $8.02
- Resistance Level
- FISI $28.12
- CRVS $8.71
- Average True Range (ATR)
- FISI 0.73
- CRVS 0.86
- MACD
- FISI 0.05
- CRVS -0.17
- Stochastic Oscillator
- FISI 85.10
- CRVS 52.25
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).